Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Depreciation & Amortization (CF) (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $442000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 18.15% year-over-year to $442000.0; the TTM value through Sep 2025 reached $1.9 million, down 16.88%, while the annual FY2024 figure was $2.2 million, 11.83% down from the prior year.
  • Depreciation & Amortization (CF) reached $442000.0 in Q3 2025 per STOK's latest filing, down from $446000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $637000.0 in Q3 2023 and bottomed at $247000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $503800.0, with a median of $540000.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 141.7% in 2023, then decreased 18.61% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $609000.0 in 2022, then rose by 2.46% to $624000.0 in 2023, then fell by 15.71% to $526000.0 in 2024, then fell by 15.97% to $442000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $442000.0 in Q3 2025, $446000.0 in Q2 2025, and $477000.0 in Q1 2025.